These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15529095)

  • 21. Summary of present data from a clinical trial of CI-719.
    Wilkening J; Schwandt P
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):90-3. PubMed ID: 1019158
    [No Abstract]   [Full Text] [Related]  

  • 22. Common questions in managing hyperlipidemia.
    Rosen IM; Sams RW
    Prim Care; 2006 Dec; 33(4):903-21. PubMed ID: 17169673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Determination of the dose-response curve of a new hypolipidemic molecule: tibric acid (CP-18524). Methodologic and statistical aspects].
    Bielmann P; Annable L; Brun D; Moorjani S; Lupien PJ; Tétreault L
    Union Med Can; 1975 Jun; 104(6):930-4. PubMed ID: 1224412
    [No Abstract]   [Full Text] [Related]  

  • 24. Deterioration in renal function associated with fibrate therapy.
    Goffin E; Devuyst O; Pirson Y
    Clin Nephrol; 2001 Jun; 55(6):490. PubMed ID: 11434364
    [No Abstract]   [Full Text] [Related]  

  • 25. Complications and side effects. Crestor tested in PHAs.
    TreatmentUpdate; 2005; 17(4):6-7. PubMed ID: 17230630
    [No Abstract]   [Full Text] [Related]  

  • 26. [Cerivastatine--profile of a new lipid-reducing drug].
    Internist (Berl); 1998 Jan; 39(1 Suppl Cerivastat):1-8. PubMed ID: 9509018
    [No Abstract]   [Full Text] [Related]  

  • 27. Reducing drug usage and adverse effects. Part III: Cardiovascular disease and hyperlipidemia.
    Baron M
    Health Care Food Nutr Focus; 2005 Jun; 22(6):7-11. PubMed ID: 15923907
    [No Abstract]   [Full Text] [Related]  

  • 28. Relation of the use of lipid-lowering medications prior to percutaneous coronary intervention to the incidence of intraprocedural adverse angiographic events.
    Ferguson MA; Romick BG; Carter LI; De Geare VS
    Am J Cardiol; 2005 Apr; 95(8):978-80. PubMed ID: 15820168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving lipid goal attainment: is it enough?
    Gotto AM
    Circulation; 2009 Jul; 120(1):3-5. PubMed ID: 19546383
    [No Abstract]   [Full Text] [Related]  

  • 30. [Antilipemic agents].
    Harlay A
    Infirm Fr; 1975 Apr; (164):29-30. PubMed ID: 1039004
    [No Abstract]   [Full Text] [Related]  

  • 31. Creatininemia during fibrate therapy: a reply to Lipscombe et al.
    Hottelart C; Achard JM; Fournier A
    Clin Nephrol; 2001 Jul; 56(1):85-6. PubMed ID: 11499666
    [No Abstract]   [Full Text] [Related]  

  • 32. Statins and polyneuropathy: setting the record straight.
    Leis AA; Stokic DS; Olivier J
    Muscle Nerve; 2005 Oct; 32(4):428-30. PubMed ID: 16094656
    [No Abstract]   [Full Text] [Related]  

  • 33. Does lipid-lowering therapy slow progression of chronic kidney disease?
    Wheeler DC
    Am J Kidney Dis; 2004 Nov; 44(5):917-20. PubMed ID: 15492960
    [No Abstract]   [Full Text] [Related]  

  • 34. [Studies on the Chinese drugs capable of reducing blood lipids].
    Peng Y
    Zhong Yao Tong Bao; 1983 Jan; 8(1):41-4. PubMed ID: 6235014
    [No Abstract]   [Full Text] [Related]  

  • 35. Evaluating lipid-lowering trials in the twenty-first century.
    Roberts WC
    Am J Cardiol; 2009 May; 103(9):1325-8. PubMed ID: 19406281
    [No Abstract]   [Full Text] [Related]  

  • 36. Lipid management in Type 1 diabetes.
    Pachaiappan KJ; Patel V; Morrissey J; Gadsby R
    Diabet Med; 2006 Mar; 23 Suppl 1():11-4. PubMed ID: 16483259
    [No Abstract]   [Full Text] [Related]  

  • 37. Managing hyperlipidemia.
    Lippincott Health Promot Lett; 1997 Feb; 2(2):6-7. PubMed ID: 9300892
    [No Abstract]   [Full Text] [Related]  

  • 38. [Novel perspective approaches to the therapy of dyslipidaemias].
    Adameová A; Kuzelová M; Svec P
    Ceska Slov Farm; 2005 May; 54(3):103-8. PubMed ID: 15945455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Some new drugs with the action on hyperlipidemia].
    Medaković M
    Med Pregl; 1968; 21(3):157-64. PubMed ID: 5192152
    [No Abstract]   [Full Text] [Related]  

  • 40. Lipid lowering activity of Eclipta prostrata in experimental hyperlipidemia.
    Kumari CS; Govindasamy S; Sukumar E
    J Ethnopharmacol; 2006 May; 105(3):332-5. PubMed ID: 16406413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.